CVKD: Cadrenal Therapeutics, Inc. Stock

by  •  • Comments Off on CVKD: Cadrenal Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 34.30
Enterprise Value ($M) 29.93
Book Value ($M) 3.41
Book Value / Share 1.91
Price / Book 10.05
NCAV ($M) 3.41
NCAV / Share 1.91
Price / NCAV 10.07

Profitability (mra)
Return on Invested Capital (ROIC) -2.23
Return on Assets (ROA) -0.89
Return on Equity (ROE) -0.99

Liquidity (mrq)
Quick Ratio 3.69
Current Ratio 3.69

Balance Sheet (mrq) ($M)
Current Assets 4.67
Assets 4.68
Liabilities 1.27
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
4 days ago 13D Pham Quang X
01-15 13G/A Murphy John Raymond
11-14 13G/A Armistice Capital, Llc 4.99 -94.38
10-04 13G Havlickova 648 a.s. 6.20

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-31 8,491 35,933 23.63
2025-01-30 5,500 31,167 17.65
2025-01-29 7,384 44,706 16.52
2025-01-28 9,339 59,518 15.69
2025-01-27 6,993 46,221 15.13

(click for more detail)

Similar Companies
CSCI – COSCIENS Biopharma Inc. CTXR – Citius Pharmaceuticals, Inc.
CUE – Cue Biopharma, Inc. CYCC – Cyclacel Pharmaceuticals, Inc.
CYCN – Cyclerion Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io